Revenue essentially flat, margins fell short of expectations
Bio-Rad Laboratories, a diagnostics company rooted in Hercules, California, closed 2025 with revenue that scarcely moved — $2.58 billion, up less than one percent — as the twin forces of geopolitical uncertainty and shrinking academic research budgets pressed against the company's core markets. The story is one familiar to science-adjacent industries in this era: the institutions that buy the tools of discovery are themselves starved for resources, and the companies that serve them must wait. Bio-Rad enters 2026 not in crisis, but in a kind of disciplined patience, generating strong cash flows while hoping the funding tide turns.
- Academic and biotech funding cuts gutted Bio-Rad's Life Science segment, which shrank 1.3% on a currency-neutral basis and continued declining even in the final quarter of the year.
- Currency headwinds compounded the pressure, stripping away what little headline growth existed and leaving full-year revenue essentially flat when adjusted.
- Clinical Diagnostics held the line with modest 0.8% growth, anchored by blood typing and quality control products, though lower Chinese reimbursement rates for diabetes testing chipped away at gains.
- The acquisition of Stilla Technologies and new oncology partnerships with Gencurix and Biodesix signal Bio-Rad is betting on precision diagnostics and cancer assays to eventually reignite growth.
- Despite margin disappointments, the company generated $375 million in free cash flow — a financial buffer that buys time as it waits for market conditions to shift.
- The 2026 outlook offers little relief: 0.5–1.5% projected growth and operating margins of 12.0–12.5% suggest a company bracing for another year of careful navigation rather than acceleration.
Bio-Rad Laboratories ended 2025 with $2.58 billion in annual revenue — a gain of just 0.7 percent that, when stripped of currency effects, amounted to almost no movement at all. CEO Norman Schwartz was candid about the forces at work: geopolitical instability and a sustained squeeze on academic research funding had hollowed out demand from the universities and research institutions that form the backbone of Bio-Rad's Life Science business, which contracted 1.3 percent on a currency-neutral basis for the year.
The company's two segments told divergent stories. Clinical Diagnostics managed modest growth of 0.8 percent, carried by quality control products and blood typing systems, though gains were partially trimmed by reduced reimbursement rates for diabetes testing in China. The fourth quarter offered a surface-level lift — total sales of $693.2 million, up 3.9 percent — but currency adjustments cut that to 1.7 percent, and Life Science continued sliding, falling 4.0 percent on a currency-neutral basis in the quarter.
Amid the stagnation, Bio-Rad made deliberate moves to position itself for a different future. The integration of Stilla Technologies expanded its droplet digital PCR portfolio, and new partnerships with Gencurix and Biodesix opened pathways into oncology diagnostics. The company also secured product registrations in more than 60 countries, bringing its clinical catalog past 1,200 offerings globally.
Cash generation remained a quiet strength — $532 million in operating cash flow and $375 million in free cash flow — even as gross and operating margins fell short of internal expectations. For 2026, Bio-Rad projects currency-neutral revenue growth of just 0.5 to 1.5 percent and operating margins between 12.0 and 12.5 percent. The company is not forecasting a reversal so much as a holding pattern, waiting to see whether research funding recovers and whether its recent strategic bets begin to pay off.
Bio-Rad Laboratories finished 2025 with revenue that barely moved. The Hercules, California-based diagnostics company reported $2.58 billion in annual sales, up just 0.7 percent from the prior year—a figure that masks deeper trouble in the research side of the business and hints at a company struggling to find momentum as it enters 2026.
The year was defined by headwinds that CEO Norman Schwartz did not shy away from naming: geopolitical uncertainty and a squeeze on academic research funding that rippled through the company's end markets. When you strip away currency fluctuations, the picture becomes even flatter. On a currency-neutral basis, full-year revenue was essentially unchanged from 2024. The company's two main business segments moved in opposite directions. The Life Science division, which serves universities and research institutions, contracted 1.3 percent on a currency-neutral basis, dragged down by the very funding pressures Schwartz cited. Clinical Diagnostics, by contrast, managed modest growth of 0.8 percent, buoyed by sales of quality control products and blood typing systems, though this gain was partially offset by lower reimbursement rates for diabetes testing in China.
The fourth quarter offered a slightly brighter picture on the surface. Total quarterly sales reached $693.2 million, up 3.9 percent from the same period a year earlier, though currency adjustments reduced that to 1.7 percent growth. Clinical Diagnostics drove the quarter, posting 8.4 percent growth in reported terms and 5.6 percent on a currency-neutral basis. Life Science, however, continued its slide, falling 2.6 percent in reported terms and 4.0 percent when adjusted for currency swings.
One bright spot for the company was the successful integration of Stilla Technologies, a digital PCR developer that Bio-Rad acquired during the year. The company signaled satisfaction with early market adoption of its expanded droplet digital PCR portfolio, a product line that represents a strategic bet on precision diagnostics. Beyond that acquisition, Bio-Rad also moved to strengthen its oncology diagnostics business through partnerships with Gencurix and Biodesix, aiming to distribute and develop in vitro diagnostic assays for cancer applications. The company also expanded its global footprint, securing new product registrations in over 60 countries, bringing its clinical diagnostics catalog to more than 1,200 products worldwide.
Despite the revenue stagnation, Bio-Rad generated substantial cash. Operating cash flow reached $532 million for the year, and free cash flow—the cash available after capital spending—totaled $375 million. This strength in cash generation provided some cushion against the margin pressures that Schwartz acknowledged fell short of expectations. Gross margins and operating margins both underperformed, a sign that the company is grappling with cost pressures even as it struggles to grow the top line.
Looking ahead, Bio-Rad is not forecasting a dramatic turnaround. For 2026, the company expects non-GAAP revenue growth of just 0.5 to 1.5 percent on a currency-neutral basis—essentially flat to barely moving. Operating margins are projected to land between 12.0 and 12.5 percent. These are cautious numbers from a company that appears to be waiting for the research funding environment to improve and for its recent acquisitions and partnerships to gain traction. The question hanging over Bio-Rad is whether the academic and biotech funding squeeze that defined 2025 will ease in the year ahead, or whether the company will need to find new ways to drive growth in a constrained market.
Citações Notáveis
2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets.— Norman Schwartz, CEO of Bio-Rad Laboratories
While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations.— Norman Schwartz, CEO of Bio-Rad Laboratories
A Conversa do Hearth Outra perspectiva sobre a história
Why did Life Science decline while Clinical Diagnostics held up?
Academic research budgets got tighter across the board in 2025. Universities and biotech companies pulled back on spending. Clinical Diagnostics is different—hospitals and diagnostic labs still need quality controls and blood typing systems regardless of the funding environment. Those are essential, recurring purchases.
The Stilla acquisition seems important. Why?
Digital PCR is a high-precision tool for measuring DNA. Stilla was a leader in next-generation versions of it. By acquiring them, Bio-Rad didn't just buy a product—they bought expertise and market position in a growing area. Early adoption signals suggest customers see value in what they're offering now.
But the margins fell short. What does that tell you?
It suggests the company is absorbing costs—integration expenses from Stilla, maybe supply chain pressures, maybe pricing pressure in certain markets. You can grow revenue and still squeeze margins if your cost structure doesn't flex downward fast enough.
The 2026 outlook is almost flat. Is that pessimism or realism?
It's realism. They're not predicting a sudden recovery in research funding. They're saying: we'll hold steady, we'll keep integrating what we've bought, and we'll wait for conditions to improve. It's a holding pattern, not a growth story.
What would change the picture?
A thaw in academic research funding would help immediately. Success with the oncology partnerships could open a new revenue stream. And if the Stilla integration drives adoption faster than expected, that could accelerate growth. But none of that is baked into the 2026 guidance.